PYXS Pyxis Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782223 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-4.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin97.1%
Operating margin-554.1%
Net margin-478.9%
FCF margin-358.7%
EBITDA margin-535.6%
Returns
ROE-62.8%
ROA-46.7%
ROIC (approx.)-65.0%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets23.2%
Debt / equity0.00x
Current ratio7.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $13.86M | $16.15M | — | — | — |
| Cost of revenue | $2.39M | $475,000 | — | — | — |
| Gross profit | $11.47M | $15.67M | — | — | — |
| R&D expense | $73.70M | $58.75M | $49.59M | $86.13M | $51.05M |
| SG&A expense | $22.19M | $25.42M | $32.61M | $37.35M | $18.66M |
| Operating income | -$84.42M | -$89.46M | -$82.20M | -$123.48M | -$69.72M |
| Pretax income | -$78.23M | -$79.50M | -$73.79M | — | — |
| Income tax | $1.39M | -$2.16M | — | — | — |
| Net income | -$79.62M | -$77.33M | -$73.79M | -$120.72M | -$75.97M |
| EBITDA | -$79.91M | -$86.48M | -$80.27M | -$122.77M | -$69.07M |
| EPS (basic) | -1.28 | -1.32 | -1.85 | -3.65 | -8.95 |
| EPS (diluted) | -1.28 | -1.32 | -1.85 | -3.65 | -8.95 |
| Weighted avg. shares (diluted) | 62.14M | 58.45M | 39.90M | 33.03M | 8.49M |
| Balance sheet | |||||
| Cash & equivalents | $15.42M | $19.47M | $9.66M | $179.29M | $274.74M |
| Short-term investments | $51.44M | $107.46M | $109.63M | — | — |
| Current assets | $72.11M | $132.44M | $124.60M | $186.61M | $278.67M |
| PP&E, net | $8.00M | $9.90M | $11.87M | $11.16M | $1.01M |
| Intangibles | $0 | $2.60M | $24.31M | — | — |
| Total assets | $91.52M | $157.18M | $173.73M | $211.38M | $280.02M |
| Current liabilities | $21.13M | $17.68M | $25.76M | $31.63M | $18.71M |
| Total liabilities | $38.11M | $36.43M | $48.02M | $50.55M | $18.71M |
| Shareholders' equity | $53.41M | $120.75M | $125.70M | $160.82M | $261.31M |
| Shares outstanding | 62.69M | 59.97M | 44.75M | 34.96M | 32.22M |
| Cash flow statement | |||||
| Operating cash flow | -$63.50M | -$57.67M | -$70.71M | -$89.33M | -$35.33M |
| Capital expenditure | $9,000 | $237,000 | $6.73M | $6.40M | $540,000 |
| Free cash flow | -$63.51M | -$57.91M | -$77.44M | -$95.73M | -$35.87M |
| Investing cash flow | $58.86M | $8.15M | -$104.85M | -$6.40M | -$590,000 |
| Financing cash flow | $594,000 | $59.33M | $5.93M | $183,000 | $304.04M |
| Depreciation & amortization | $4.51M | $2.98M | $1.93M | $709,000 | $647,000 |
| Stock-based compensation | $11.80M | $12.95M | $16.95M | $15.76M | $6.44M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.